Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/4775
Title: | Exploring strategies to prevent post-lobectomy space: Transient diaphragmatic paralysis using Botulinum toxin type A (BTX-A) | Authors: | Kaya, Şeyda Örs. Atalay, Habib. Erbay, Hakan Rıza. Özcan, Ali Vefa. Gökşin, İbrahim Kabay, Burhan. Tekin, K. |
Keywords: | antibiotic agent botulinum toxin A diclofenac sodium chloride animal experiment animal model article controlled study diaphragm paralysis drug efficacy hemidiaphragm lung lobectomy male nonhuman peroperative care postoperative infection postoperative pain postoperative period preoperative evaluation rabbit randomization rib statistical significance thorax radiography |
Abstract: | Objective: Various techniques to reduce air space after pulmonary lobectomy especially for lung cancer have been an important concern in thoracic surgical practice. The aim of this study was to assess the effectiveness of Botulinum toxin A (BTX-A) injection into the diaphragm to reduce air space after right lower pulmonary lobectomy in an animal model. Methods: Twelve male New Zealand rabbits were randomly allocated into two groups. All animals underwent right lower lobectomy. Then, normal saline of 0,1 ml and 10 units of 0,1 ml Botulinum toxin type A were injected into the muscular part of the right hemidiaphragm in control (n=6) and BTX-A groups (n=6) respectively. Residual air space and diaphragmatic elevation were evaluated with chest X-ray pre- and postoperatively. Diaphragmatic elevation was measured as a distance in millimetre from the line connecting the 10th ribs to the midpoint of the right hemidiaphragm. Results: The mean diaphragmatic elevation in BTX-A and control groups were 7.0±2.5 and 1.3±1.2 millimetres respectively. Diaphragmatic elevations were significantly higher in BTX-A group (p=0.0035). Conclusion: Intraoperative Botulinum toxin type A injection may reduce postlobectomy spaces effectively via hemidiaphragmatic paralysis in rabbits. Further studies are needed to validate the safe use of Botulinum toxin type A in human beings. © 2005 Ors Kaya et al., licensee BioMed Central Ltd. | URI: | https://hdl.handle.net/11499/4775 https://doi.org/10.1186/1477-7800-2-21 |
ISSN: | 1477-7800 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
SCOPUSTM
Citations
6
checked on Dec 14, 2024
Page view(s)
60
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.